Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring

Fig. 4

Loss of target circRNAs attenuates CCA proliferation and EMT in vivo. a Schematic representation of circRNA-specific ASO treatment in balb/c nude mice. CCLP-1 cells were subcutaneously injected into the right flank to establish a tumor-bearing model and randomized into ASO-NC group (n = 5), ASO-367 group (n = 5), ASO-21647 group (n = 5) and ASO-288 group (n = 5) 7 days following tumor implantation. b ASO treatment of each target circRNA leads to reduced tumor volume 22 days following tumor implantation. Expression of Ki-67, Vimentin, β-catenin, and E-cadherin were evaluated in harvested tumor by c immunohistochemistry and d immunoblotting. Scale bar: 100 μm. *P < 0.05; **P < 0.01; ***P < 0.001; \({{\rm{n}}.{\rm{s}}.\atop }{\rm{not}}\;{\rm{significant}}\); (two-way ANOVA with Turkey’s multiple-comparison test for curve comparison; two tail unpaired Student’s t test for continuous variables, presented as mean ± SD)

Back to article page